ArticleFrontiers in oncology2025
Intratumoral and peritumoral multiparametric MRI-based radiomics nomogram for preoperative risk stratification in patients with endometrial cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intratumoral and peritumoral MRI habitat imaging for differentiating stage IA endometrial cancer from benign endometrial lesions: a multicenter study.Frontiers in oncology · 2026Article
- Preoperative risk stratification in endometrial carcinoma: a pragmatic, complementary nomogram using readily available clinical variables.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Achieving accurate preoperative risk stratification for endometrial cancer (EC) is challenging due to the need for histopathology to obtain the necessary parameters. This study aimed to establish and validate a multiparametric magnetic resonance imaging (MRI) radiomics nomogram that incorporates the peritumoral region for preoperative risk stratification in EC patients. Methods: Three-hundred seventy-four women with histologically confirmed EC were divided into training (1.5-T MRI, n=163), test (1.5-T MRI, n=70), and independent validation (3.0-T MRI, n=141) cohorts. As per the guidelines of the European Society of Medical Oncology, patients were categorized into four risk groups: low, intermediate, high-intermediate, and high. Binary classification models were subsequently constructed to distinguish between low- and non-low-risk individuals. Radiomic features were extracted from intra- and peritumoral regions via T2-weighted imaging (T2WI) and apparent diffusion coefficient (ADC) maps. Feature selection was carried out via univariate analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate logistic regression. A radiomic model (radscore) was established using the selected features. A nomogram combining the radscore and most predictive clinical parameters was developed. Decision curve analysis (DCA) and the net reclassification index (NRI) were used to assess the clinical benefit of the nomogram. Results: Nine radiomic features were selected from intra- and peritumoral regions on ADC maps and T2W images. The nomogram combining the radscore, age, maximum anteroposterior tumor diameter on sagittal T2WI (APsag), and the tumor area ratio (TAR), achieved the highest area under the curve (AUC) values across all cohorts (training: 0.949, test: 0.947, independent validation: 0.909). The nomogram demonstrated superior performance compared to the radscore (AUCtraining = 0.929, AUCtest = 0.917, and AUCindependent validation = 0.813) alone and the clinical model (AUCtraining = 0.855, AUCtest = 0.845, and AUCindependent validation = 0.842). DCA and the NRI demonstrated that the nomogram achieved greater diagnostic performance and net clinical benefits than did the radscore alone. Conclusion: The developed MRI radiomics nomogram achieved high diagnostic performance in classifying low- and non-low-risk EC preoperatively. This tool could provide valuable support for therapeutic decision-making and demonstrates robustness across various field strength data, increasing its potential for widespread clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.